Pharsight

Apriso patents expiration

APRISO IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6551620 SALIX Pellet formulation for the treatment of the intestinal tract
Apr, 2018

(6 years ago)

US8940328 SALIX Pellet formulation for the treatment of the intestinal tract
Apr, 2018

(6 years ago)

US8496965 SALIX Pellet formulation for the treatment of the intenstinal tract
Apr, 2018

(6 years ago)

US8911778 SALIX Pellet formulation for the treatment of the intestinal tract
Apr, 2018

(6 years ago)

US8337886 SALIX Pellet formulation for the treatment of the intestinal tract
Apr, 2018

(6 years ago)

US8956647 SALIX Pellet formulation for the treatment of the intestinal tract
Apr, 2018

(6 years ago)

US8865688 SALIX Compositions and methods for treatment of bowel diseases with granulated mesalamine
May, 2030

(5 years from now)

Apriso is owned by Salix.

Apriso contains Mesalamine.

Apriso has a total of 7 drug patents out of which 6 drug patents have expired.

Expired drug patents of Apriso are:

  • US6551620
  • US8940328
  • US8496965
  • US8911778
  • US8337886
  • US8956647

Apriso was authorised for market use on 31 October, 2008.

Apriso is available in capsule, extended release;oral dosage forms.

Apriso can be used as for the maintenance of remission of ulcerative colitis in subjects 18 years of age and older, for the maintenance of remission of ulcerative colitis.

The generics of Apriso are possible to be released after 01 May, 2030.

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Oct 31, 2011

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using MESALAMINE ingredient

Market Authorisation Date: 31 October, 2008

Treatment: For the maintenance of remission of ulcerative colitis in subjects 18 years of age and older; For the maintenance of remission of ulcerative colitis

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

How can I launch a generic of APRISO before it's drug patent expiration?
More Information on Dosage

APRISO family patents

Family Patents